An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hypertrophic Cardiomyopathy,covid-19
  • Age: Between 18 years - 85 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Able to comprehend and willing to sign an ICF and willing to comply with all study procedures and restrictions
    2. Completion of a Cytokinetics study investigating CK-3773274
    3. Left ventricular ejection fraction = 55%
    4. Male patients are eligible to participate if they agree to the following during the study and for at least 10 weeks after the last dose of IP
    5. A female patient is eligible to participate if she is not pregnant, breastfeeding or planning to donate eggs, and is not a woman of childbearing potential OR Is a WOCBP and using a highly effective method of contraceptive
    6. Willing and able to complete all screening procedures

You may not be eligible for this study if the following are true:

    1. Has received treatment with mavacamten
    2. Has participated in another investigational device or drug study or received an investigational device or drug <1 month (or 5 half-lives for drugs, whichever is longer) prior to screening
    3. Has any acute or serious comorbid condition (e.g., major infection or hematologic, oncologic, cardiac, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the opinion of the site Principal Investigator/designee or Medical Monitor, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion
    4. Has developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment
    5. Has undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation) since the completion of a prior study of CK-3773274
    6. Has moderate or severe aortic valve stenosis 09 December 2021
    7. Had a confirmed LVEF <40% with an associated dose interruption during CY 6021 or CY 6031
    8. History of syncope or sustained ventricular tachyarrhythmia with exercise within 30 days prior to screening
    9. History of ICD placement within 30 days prior to screening.
    10. Hypersensitivity to excipients in CK-3773274 Tablets, Film-Coated.
    11. Does not consent to participate in CMR sub-study
    12. Inability to tolerate CMR
    13. Has an implantable cardioverter-defibrillator (ICD)
    14. Has a cardiac pacemaker



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.